Showing results (1-10 of 182) with videos related to
Sort By:
Pageof 19
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 1, 2018
Modern Radiopharmaceutical Dosimetry Should Include Robust Biodistribution ReportingAdam L Kesner, Lisa BodeiJournal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 26, 2025
Extravasation Frequency of [<sup>177</sup>Lu]Lu-DOTATATE: Insights and Implications Derived from 1,314 Cycles of Treated Patients-A Single-Site AnalysisGunjan Kayal, Finn Augensen, Lisa Bodei, et al.PET Clinics|March 1, 2023
Neuroendocrine Tumor Therapy Response AssessmentVetri Sudar Jayaprakasam, Lisa BodeiClinical Nuclear Medicine|January 29, 2019
Hepatocellular Carcinoma Mimicking Neuroendocrine Tumor Metastasis on 68Ga-DOTATATE PET/CTGary A Ulaner, Lisa BodeiReviews in Endocrine & Metabolic Disorders|March 30, 2021
Imaging of neuroendocrine tumors: A pictorial review of the clinical value of different imaging modalitiesAli Pirasteh, Petra Lovrec, Lisa BodeiPET Clinics|July 18, 2014
Yttrium-based therapy for neuroendocrine tumorsLisa Bodei, Marta Cremonesi, Giovanni PaganelliThoracic Surgery Clinics|July 29, 2014
A historical appreciation of bronchopulmonary neuroendocrine neoplasia: resolution of a carcinoid conundrumIrvin M Modlin, Lisa Bodei, Mark KiddJournal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 28, 2019
Is the Vision of Radioligand Therapy for Prostate Cancer Becoming a Reality? An Overview of the Phase III VISION Trial and Its Importance for the Future of TheranosticsKambiz Rahbar, Lisa Bodei, Michael J MorrisCurrent Opinion in Endocrinology, Diabetes, and Obesity|December 3, 2015
Chromogranin A: any relevance in neuroendocrine tumors?Mark Kidd, Lisa Bodei, Irvin M ModlinSeminars in Radiation Oncology|November 28, 2020
The Role of Theranostics in Prostate CancerElisabeth O'Dwyer, Lisa Bodei, Michael J MorrisPageof 19